NCT01670032已完成2 期
A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 328
- 试验地点
- 26
- 主要终点
- Clinical Success at Follow up (Day 15) in the intent-to-treat (ITTC) population
研究概览
简要总结
This study will be a multicenter, randomized, vehicle controlled, parallel, group, double blind study. Eligible subjects with a clinical diagnosis of impetigo will be randomized to one of four treatment groups: 1.5% CD07223 Topical Gel applied BID; 1.5% CD07223 Topical Gel applied TID; Vehicle Topical Gel applied BID;Vehicle Topical Gel applied TID. All treatments will be administered for 7 days. Disease activity for the Target Lesion will be evaluated using the Skin Infection Rating Scale (SIRS) Score.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female 2 years of age or older
- •Clinical diagnosis of primary impetigo (bullous or non bullous)
- •Minimum diameter of Target Lesion to be one centimeter measured either as length or width.
- •Presence of at least one and no more than ten lesions per subject at the time of screening
- •The infected lesions' total area (as determined by the Investigator) must be less than 100 cm2 in total area for subjects 18 years of age or older, or up to a maximum of 2% total body surface area for subjects younger than 18 years of age.
- •Skin Infection Rating Scale (SIRS) total score of the Target Lesion of at least 4
排除标准
- •Presence of other active skin diseases at or near the Target Lesion area to be treated
- •A subject whose disease is so widespread or severe that, in the opinion of the investigator, oral antibiotic treatment is needed
- •Signs and symptoms of another current infection requiring antibiotic treatment
- •Tympanic temperature at Screening/Baseline exceeding 38 degrees Celsius (100.4 degrees Fahrenheit) in a pediatric subject or 37.8 degrees Celsius (100 degrees Fahrenheit) in an adult subject
- •History of Hepatitis B or C, HIV/ AIDS, or other immunodeficiency disease
- •Concurrent or recent scabies infection or lice infestation (pediculosis) of the scalp
- •Use of systemic antibiotics or systemic steroids within 14 days prior to study entry. A history of three or more courses of systemic antibiotics within the 3 month period immediately prior to screening will also be considered exclusionary
- •Use of topical antibiotics, topical antibacterials, topical antifungals or topical steroids within 14 days prior to study entry on any skin lesion (as deemed significant by the Investigator by virtue of the lesion's nature and/or position to impact on the effectiveness of the study drug)
- •Participation in any other clinical study or use of any investigational drugs or investigational device within 30 days prior to enrollment
- •Presence of secondarily infected traumatic lesions (e.g. surgical wounds, animal/insect bites, burns, lacerations and abrasions).
- •Another family member in same household currently enrolled in this study or another family member in the same household with active impetigo
结局指标
主要结局
Clinical Success at Follow up (Day 15) in the intent-to-treat (ITTC) population
时间窗: 2 weeks
Clinical Success is defined by the SIRS score of the Target Lesion
次要结局
未报告次要终点
研究者
研究点 (26)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice.Head LiceNCT00301327Summers Laboratories120
已完成
不适用
Clinical Investigation on the Efficacy and Safety of Relizema Cream in Paedriatric PatientsAtopic DermatitisNCT05259774Relife S.r.l.60
已完成
2 期
A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque PsoriasisPsoriasisPlaque PsoriasisNCT01610596Therapeutics, Inc.72
已完成
3 期
Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne VulgarisAcne VulgarisNCT03522441Akorn, Inc.1,125
已完成
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque PsoriasisPsoriatic PlaqueNCT03630939Escalier Biosciences B.V.104